2017
Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck
Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.Peer-Reviewed Original ResearchNeck cancerSecond primary tumorsExtensive clinical researchCancer-related mortalityNovel molecular targetsWhole-exome sequencingBiologic agentsOral leukoplakiaInvasive cancerPrimary tumorClinical trialsPrecursor lesionsNovel molecular pathwaysPrimary headMucosal fieldTumor specimensNeck regionCare optionsClinical researchCancerDriver mutationsExome sequencingMolecular targetsGenetic mutationsMolecular pathways
2014
HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma Epidemiology and Prevention
Galloway T, Davis K, Burtness B, Ferris R, Mehra R, Ridge J, Flieder D, Duvvuri U. HPV Association and the Increasing Incidence of Unknown Primary Head-and-Neck Squamous Cell Carcinoma Epidemiology and Prevention. International Journal Of Radiation Oncology • Biology • Physics 2014, 88: 494. DOI: 10.1016/j.ijrobp.2013.11.102.Peer-Reviewed Original Research
2010
Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen C. Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: 1020-1025. PMID: 20231078, DOI: 10.1016/j.ijrobp.2009.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, Squamous CellCetuximabCombined Modality TherapyDrug Administration ScheduleErlotinib HydrochlorideFeasibility StudiesFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalProtein Kinase InhibitorsQuinazolinesRadiotherapy DosageRetreatmentTreatment OutcomeConceptsDose-limiting toxicityMaintenance erlotinibPrimary HNCCohort IIICohort IINeck cancerCohort IPrimary headRadiation therapyPhase I dose-escalation trialPercutaneous endoscopic gastrostomy (PEG) tube placementAcute grade 3 toxicityGrade 4 acute toxicityI dose-escalation trialEndoscopic gastrostomy tube placementGrade 3 dysphagiaGrade 3 osteoradionecrosisNew primary headGrade 3 toxicityDose-escalation trialPhase I trialGastrostomy tube placementErlotinib dailyMaintenance therapyPrior radiation
2009
Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer
Rusthoven K, Feigenberg S, Raben D, Kane M, Song J, Nicolaou N, Mehra R, Burtness B, Swing R, Chen C. Initial Results of a Phase I Dose Escalation Trial of Concurrent and Maintenance Erlotinib and Re-irradiation for Recurrent and New Primary Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s408. DOI: 10.1016/j.ijrobp.2009.07.935.Peer-Reviewed Original Research